nodes	percent_of_prediction	percent_of_DWPC	metapath
Amcinonide—ANXA1—forebrain—attention deficit hyperactivity disorder	0.0621	0.165	CbGeAlD
Amcinonide—ANXA1—cardiovascular system—attention deficit hyperactivity disorder	0.0525	0.14	CbGeAlD
Amcinonide—ANXA1—midbrain—attention deficit hyperactivity disorder	0.041	0.109	CbGeAlD
Amcinonide—ANXA1—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.0357	0.0573	CbGpPWpGaD
Amcinonide—ANXA1—nervous system—attention deficit hyperactivity disorder	0.0337	0.0896	CbGeAlD
Amcinonide—ANXA1—central nervous system—attention deficit hyperactivity disorder	0.0325	0.0863	CbGeAlD
Amcinonide—ANXA1—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.032	0.0513	CbGpPWpGaD
Amcinonide—ANXA1—cerebellum—attention deficit hyperactivity disorder	0.0317	0.0843	CbGeAlD
Amcinonide—ANXA1—brain—attention deficit hyperactivity disorder	0.0258	0.0685	CbGeAlD
Amcinonide—NR3C1—forebrain—attention deficit hyperactivity disorder	0.0216	0.0573	CbGeAlD
Amcinonide—ANXA1—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.0214	0.0344	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0194	0.031	CbGpPWpGaD
Amcinonide—NR3C1—cardiovascular system—attention deficit hyperactivity disorder	0.0182	0.0485	CbGeAlD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.017	0.0273	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0167	0.0268	CbGpPWpGaD
Amcinonide—ANXA1—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.0149	0.0239	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.0146	0.0233	CbGpPWpGaD
Amcinonide—NR3C1—midbrain—attention deficit hyperactivity disorder	0.0142	0.0379	CbGeAlD
Amcinonide—ANXA1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.013	0.0208	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.0127	0.0204	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0127	0.0204	CbGpPWpGaD
Amcinonide—NR3C1—nervous system—attention deficit hyperactivity disorder	0.0117	0.0311	CbGeAlD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0116	0.0186	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.0115	0.0184	CbGpPWpGaD
Amcinonide—NR3C1—central nervous system—attention deficit hyperactivity disorder	0.0113	0.03	CbGeAlD
Amcinonide—ANXA1—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.0113	0.0181	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.0111	0.0178	CbGpPWpGaD
Amcinonide—NR3C1—cerebellum—attention deficit hyperactivity disorder	0.011	0.0293	CbGeAlD
Amcinonide—ANXA1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0109	0.0175	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.0104	0.0166	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.0101	0.0163	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0101	0.0162	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00993	0.0159	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00941	0.0151	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00911	0.0146	CbGpPWpGaD
Amcinonide—NR3C1—brain—attention deficit hyperactivity disorder	0.00895	0.0238	CbGeAlD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00895	0.0144	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00884	0.0142	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00881	0.0141	CbGpPWpGaD
Amcinonide—ANXA1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00871	0.014	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00824	0.0132	CbGpPWpGaD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00779	0.0125	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0077	0.0124	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00733	0.0118	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00719	0.0115	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00716	0.0115	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00694	0.0111	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00682	0.0109	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00673	0.0108	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00666	0.0107	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00653	0.0105	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00649	0.0104	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00627	0.0101	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00587	0.00941	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00577	0.00925	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00558	0.00895	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00548	0.00878	CbGpPWpGaD
Amcinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—attention deficit hyperactivity disorder	0.00533	0.00855	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00519	0.00832	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00519	0.00832	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00498	0.00799	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00458	0.00734	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00454	0.00728	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00452	0.00725	CbGpPWpGaD
Amcinonide—ANXA1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00439	0.00705	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00435	0.00698	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00405	0.00649	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of Androgen receptor activity—EP300—attention deficit hyperactivity disorder	0.004	0.00641	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00395	0.00634	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00393	0.00631	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00392	0.00629	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.0039	0.00626	CbGpPWpGaD
Amcinonide—NR3C1—Circadian Clock—EP300—attention deficit hyperactivity disorder	0.00388	0.00623	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00385	0.00618	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00385	0.00618	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00381	0.0061	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00378	0.00606	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00377	0.00604	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00368	0.00589	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00356	0.00571	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00355	0.00568	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.0035	0.00561	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00346	0.00554	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00322	0.00516	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.0032	0.00513	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00318	0.0051	CbGpPWpGaD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—attention deficit hyperactivity disorder	0.00285	0.00457	CbGpPWpGaD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.00282	0.00452	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00267	0.00428	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00248	0.00398	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00234	0.00375	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00225	0.00362	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00217	0.00348	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.0021	0.00337	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00207	0.00331	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00204	0.00327	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.0019	0.00305	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.00169	0.00271	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00169	0.0027	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00133	0.00214	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000706	0.00113	CbGpPWpGaD
